Notice of Faron Pharmaceuticals LTD's Annual General Meeting

About this update from Faron Pharmaceuticals Oy

TURKU, FI / ACCESS Newswire / April 10, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Shareholders of Faron Pharmaceuticals Ltd (the "Company") are notified of the Annual General Meeting (the "AGM") to be held on 4 May 2026 at 10:00 a.m. EEST (Finnish time) at Putous auditorium at Vierailukeskus JOKI, 2. floor, Lemminkäisenkatu 12 B, FI-20520 Turku, Finland. The registration of attendees and the distribution of voting slips will commence at the meeting venue at 9:30 a.m. EEST (Finnish time). The Company's Annual Report 2025 is available for review and downloading on the Company's website at https://www.faron.com/. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING At the AGM the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Presentation of the financial statements, the report of the Board of Directors and the auditor's report for 2025 Review by the CEO. 7. Adoption of the financial statements 8. Resolution on the use of the profit shown on the balance sheet and the payment of dividend The Board of Directors (the "Board") proposes that no dividend for the financial year 2025 will be paid and that the losses of the Company for the financial year, amounting to EUR 27.2 million (IFRS), will be carried forward to the reserve for invested unrestricted equity. 9. Resolution on the discharge of the members of the Board and the CEO of the Company from liability 10. Resolution on the remuneration of the members of the Board The Shareholders' Nomination Board proposes that the annual remuneration of the members of the Board remain unchanged and that EUR 35,000 will be paid to the Board members, in addition to which an annual remuneration of EUR 35,000 will be paid to the chair of the Board. In addition, the Shareholders' Nomination Board proposes that a further annual remuneration of EUR 11,000 will be paid to the chair of the audit committee, a further annual remuneration of EUR 9,000 will be paid to the chair of the remuneration committee and a further annual remuneration of EUR 6,000 will be paid to the chair of the nomination committee. In addition...

View stock analysis, news, and events for Faron Pharmaceuticals Oy